- Latest available (Revised)
- Point in Time (15/02/2018)
- Original (As made)
Point in time view as at 15/02/2018.
There are currently no known outstanding effects for the The Blood Safety and Quality Regulations 2005, Section 25.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
25.—(1) The Medicines Act 1968 shall be amended as follows—
(a)in section 7 (general provisions as to dealing with medicinal products) omit paragraph (a) of subsection (6A) M1;
(b)in section 8 (provisions as to manufacture and wholesale dealing), omit paragraph (a) of subsection (4) M2;
(c)in section 130 (meaning of “medicinal product” and related expressions) in subsection (5), after paragraph (b), insert the following new paragraph—
“(ba) whole human blood and human blood components;”.
(d)In section 130, after subsection (5A) insert the following new subsection—
“(5B) For the purposes of this section, “human blood component” means any of the following constituents of human blood: red cells, white cells, platelets and plasma.”.
(2) The Medicines (Standard Provisions for Licenses and Certificates) Regulations 1971 shall be amended as follows—
(a)in regulation 2 (interpretation), after the definition of “BCG vaccine” insert the following definitions—
““blood” means whole human blood;
“blood component” means a therapeutic constituent of blood (red cells, white cells, platelets and plasma);”; and
(b)in Schedule 2 insert the following new paragraph—
“5C. The licence holder shall ensure that any blood or blood component imported into the United Kingdom and used by him as a starting material or raw material in the manufacture of a medicinal product, shall meet equivalent standards of quality and safety to those laid down in Commission Directive 2004/33/EC, implementing Directive 2003/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components.”.
(3) In the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994 M3, in regulation 1 (citation, commencement and interpretation), in paragraph (2), in the definition of “the 2001 Directive”, after “as amended by” insert— “ Directive 2002/98/EC of the European Parliament and of the Council setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC, ”.
Marginal Citations
M1Subsection (6A) was inserted by S.I. 1992/604 and amended by S.I. 1994/276.
M2Subsection (4) was substituted by S.I. 1992/604 and amended by S.I. 1994/276.
M3S.I. 1994/3144; relevant amending instruments are S.I. 2001/795, 2002/236, 2003/2321 and 2004/3224.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: